Figure 5
Effect of BIBB-515 and YM-53601 on chemoimmuno-sensitivity. MEC-2 cells were treated with 10 μM fludarabine (F), 10 μg/ml rituximab (R) or their combinations (F + R) in the presence or absence of 10 μM either BIBB-515 (B, panel A) or YM-53601 (Y, panel B) for 3 days, and analyzed cell viability by MTT assay. The values of treated with BIBB-515 or YM-53601 samples (n = 16) were statistically different from the controls (C). *P < 0.05. **P < 0.01.